Earnings results for Aileron Therapeutics (NASDAQ:ALRN)
Aileron Therapeutics, Inc. is estimated to report earnings on 11/12/2020. The upcoming earnings date is derived from an algorithm based on a company’s historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 2 analysts’ forecasts, the consensus EPS forecast for the quarter is $-0.1. The reported EPS for the same quarter last year was $-0.28.
Aileron Therapeutics last announced its quarterly earnings data on August 5th, 2020. The reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.05. Aileron Therapeutics has generated ($1.20) earnings per share over the last year. Aileron Therapeutics has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Thursday, November 12th, 2020 based off prior year’s report dates.
Analyst Opinion on Aileron Therapeutics (NASDAQ:ALRN)
3 Wall Street analysts have issued ratings and price targets for Aileron Therapeutics in the last 12 months. Their average twelve-month price target is $3.50, predicting that the stock has a possible upside of 212.50%. The high price target for ALRN is $5.00 and the low price target for ALRN is $2.00. There are currently 3 buy ratings for the stock, resulting in a consensus rating of “Buy.”
Aileron Therapeutics has received a consensus rating of Buy. The company’s average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings. According to analysts’ consensus price target of $3.50, Aileron Therapeutics has a forecasted upside of 212.5% from its current price of $1.12. Aileron Therapeutics has received no research coverage in the past 90 days.
Dividend Strength: Aileron Therapeutics (NASDAQ:ALRN)
Aileron Therapeutics does not currently pay a dividend. Aileron Therapeutics does not have a long track record of dividend growth.
Insiders buying/selling: Aileron Therapeutics (NASDAQ:ALRN)
In the past three months, Aileron Therapeutics insiders have not sold or bought any company stock. Only 4.90% of the stock of Aileron Therapeutics is held by insiders. Only 9.94% of the stock of Aileron Therapeutics is held by institutions.
Earnings and Valuation of Aileron Therapeutics (NASDAQ:ALRN
Earnings for Aileron Therapeutics are expected to grow in the coming year, from ($0.54) to ($0.36) per share. The P/E ratio of Aileron Therapeutics is -1.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Aileron Therapeutics is -1.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Aileron Therapeutics has a P/B Ratio of 1.93. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.
More latest stories: here